Atavistik Bio’s high-throughput platform for the unbiased identification of metabolite-protein interactions, will enable us to discover first-in-class drugs inspired and empowered by nature’s own mechanisms of allosteric control. Our unique approach marries this validated platform with structure-aided drug design capabilities and cutting-edge insights into the regulation of metabolic systems—including clinical metabolomic data sets—to apply to genetically-validated targets in metabolic diseases and cancer.

Founders

Jared Rutter, PhD
Jared Rutter, PhD
Professor of Biochemistry
University of Utah
HHMI Investigator
Ralph J DeBerardinis, MD, PhD
Ralph J DeBerardinis, MD, PhD
Professor, Children’s Research Institute
University of Texas Southwestern Medical Center
HHMI Investigator
News
August 24, 2021
Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer
Careers
Join our team as we expand into our new Cambridge-based location.

Investors

TCG
LUX
Nextech